Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …

In the last several decades, the number of people dying from cancer-related deaths has not
reduced significantly despite phenomenal advances in the technologies related to diagnosis …

FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is expressed almost
exclusively in the hematopoietic compartment. Its ligand, FLT3 ligand (FL), induces …

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly
diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately …

Introduction: The JAK kinases are a family of four tyrosine receptor kinases that play a
pivotal role in cytokine receptor signalling pathways via their interaction with signal …

This review describes the recently FDA-approved drugs (in the year 2022). Many of these
products contain active moieties that FDA had not previously approved, either as a single …

Immortalized cell lines are widely used in vitro tools in oncology and hematology research.
While these cell lines represent artificial systems and may accumulate genetic aberrations …

Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by
anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis …

JAK-STAT (Janus associated kinase-signal transducer and activator of transcription)
pathway plays a critical role in transduction of extracellular signals from cytokines and …

Following the discovery of the JAK2V617F mutation in myeloproliferative neoplasms in
2005, fedratinib was developed as a small molecular inhibitor of JAK2. It was optimized to …